You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Catalyst Biosciences closes $115M common stock offering
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective
Catalyst Biosciences Inc. closed its underwritten public offering of 3,382,352 common shares at $34 apiece with gross proceeds of about $115 million.
The shares include the full exercise of the underwriters' option to buy an additional 441,176 shares.
JonesTrading Institutional Services LLC acted as sole book-running manager and Ladenburg Thalmann & Co. Inc. acted as joint book runner.
LifeSci Capital LLC acted as lead manager and B. Riley FBR Inc. acted as co-manager of the offering.